\BOOKMARK [1][-]{section.1}{Introduction.}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Genome engineering.}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Clustered Regularly Interspaced Short Palindromic Repeats \(CRISPR\).}{section.1}% 3
\BOOKMARK [3][-]{subsubsection.1.2.1}{Type II CRISPR-Cas system.}{subsection.1.2}% 4
\BOOKMARK [2][-]{subsection.1.3}{Cas9 Variants.}{section.1}% 5
\BOOKMARK [2][-]{subsection.1.4}{Project aim.}{section.1}% 6
\BOOKMARK [1][-]{section.2}{Materials and Methods.}{}% 7
\BOOKMARK [2][-]{subsection.2.1}{Expression and purification of Cas9.}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.2}{Cas9 Stability and Structural analysis.}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.3}{In vitro assays.}{section.2}% 10
\BOOKMARK [3][-]{subsubsection.2.3.1}{PCR amplification of target region.}{subsection.2.3}% 11
\BOOKMARK [3][-]{subsubsection.2.3.2}{Cas9 RNP assembly and in vitro activity assays.}{subsection.2.3}% 12
\BOOKMARK [2][-]{subsection.2.4}{In vivo assays.}{section.2}% 13
\BOOKMARK [3][-]{subsubsection.2.4.1}{Cas9 RNP assembly and lipofection.}{subsection.2.4}% 14
\BOOKMARK [3][-]{subsubsection.2.4.2}{PCR amplification of target region.}{subsection.2.4}% 15
\BOOKMARK [3][-]{subsubsection.2.4.3}{T7 endonuclease I assay}{subsection.2.4}% 16
\BOOKMARK [1][-]{section.3}{Results.}{}% 17
\BOOKMARK [2][-]{subsection.3.1}{Purification.}{section.3}% 18
\BOOKMARK [2][-]{subsection.3.2}{Stability and Structural analysis.}{section.3}% 19
\BOOKMARK [2][-]{subsection.3.3}{Functional analysis.}{section.3}% 20
\BOOKMARK [1][-]{section.4}{Discussion.}{}% 21
\BOOKMARK [2][-]{subsection.4.1}{Analysis of self-produced Cas9 proteins.}{section.4}% 22
\BOOKMARK [2][-]{subsection.4.2}{Protein transfection.}{section.4}% 23
\BOOKMARK [2][-]{subsection.4.3}{Limitations of SpyCas9 proteins.}{section.4}% 24
\BOOKMARK [1][-]{section.5}{Conclusion.}{}% 25
